DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that clinical data on aripiprazole lauroxil, an investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia, and ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia, are scheduled to be presented at the 15th International Congress on Schizophrenia Research (ICOSR) in Colorado Springs, Colo., March 28-April 1, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
